Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liraglutide + metformin
- Development stage
- Phase 4
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Oral
01
Overview
Liraglutide + metformin is a combination therapy being investigated for the treatment of obesity and associated metabolic disorders. Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying to promote satiety and weight loss. Metformin is a biguanide that primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, often through the activation of AMP-activated protein kinase (AMPK). This specific combination is being evaluated by Xiangya Hospital of Central South University in a Phase 2 clinical trial to determine its efficacy in weight loss and metabolic improvement in obese Chinese patients, particularly those who do not achieve adequate glycemic control with liraglutide monotherapy. The study also explores pharmacogenomic predictors to identify genetic factors influencing the curative effect of the treatment.
- Other names
- liraglutide and metformin combination
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)GLP1R (GLP-1R)PKA (Cyclic amp-dependent protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on liraglutide + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liraglutide + metformin.